These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 21417729)

  • 1. Regulatory considerations for development of bioanalytical assays for biotechnology products.
    Swann PG; Shapiro MA
    Bioanalysis; 2011 Mar; 3(6):597-603. PubMed ID: 21417729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioanalytical considerations in the comparability assessment of biotherapeutics.
    Lee JW; Wang YM; Moxness M; DeSilva B
    Bioanalysis; 2011 Mar; 3(6):613-22. PubMed ID: 21417731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capsule review on bioanalytical method transfer: opportunities and challenges for chromatographic methods.
    Lin ZJ; Li W; Weng N
    Bioanalysis; 2011 Jan; 3(1):57-66. PubMed ID: 21175367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products.
    Shankar G; Devanarayan V; Amaravadi L; Barrett YC; Bowsher R; Finco-Kent D; Fiscella M; Gorovits B; Kirschner S; Moxness M; Parish T; Quarmby V; Smith H; Smith W; Zuckerman LA; Koren E
    J Pharm Biomed Anal; 2008 Dec; 48(5):1267-81. PubMed ID: 18993008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of competitive ligand-binding assay and bioassay formats for the measurement of neutralizing antibodies to protein therapeutics.
    Finco D; Baltrukonis D; Clements-Egan A; Delaria K; Gunn GR; Lowe J; Maia M; Wong T
    J Pharm Biomed Anal; 2011 Jan; 54(2):351-8. PubMed ID: 20863644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Old to new ligand-binding assay method modifications.
    Stouffer B; Stocker D
    Bioanalysis; 2016 Jul; 8(13):1403-7. PubMed ID: 27302308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspects of bioanalytical method validation for the quantitative determination of trace elements.
    Levine KE; Tudan C; Grohse PM; Weber FX; Levine MA; Kim YS
    Bioanalysis; 2011 Aug; 3(15):1699-712. PubMed ID: 21827269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing specificity for immunogenicity assays.
    Swanson SJ; Chirmule N
    Bioanalysis; 2009 Jun; 1(3):611-7. PubMed ID: 21083156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How to systematically evaluate immunogenicity of therapeutic proteins - regulatory considerations.
    Jahn EM; Schneider CK
    N Biotechnol; 2009 Jun; 25(5):280-6. PubMed ID: 19491045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products.
    Mire-Sluis AR; Barrett YC; Devanarayan V; Koren E; Liu H; Maia M; Parish T; Scott G; Shankar G; Shores E; Swanson SJ; Taniguchi G; Wierda D; Zuckerman LA
    J Immunol Methods; 2004 Jun; 289(1-2):1-16. PubMed ID: 15251407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in high-throughput quantitative bioanalysis by LC-MS/MS.
    Xu RN; Fan L; Rieser MJ; El-Shourbagy TA
    J Pharm Biomed Anal; 2007 Jun; 44(2):342-55. PubMed ID: 17360141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioanalytical methods for the quantification of therapeutic monoclonal antibodies and their application in clinical pharmacokinetic studies.
    Damen CW; Schellens JH; Beijnen JH
    Hum Antibodies; 2009; 18(3):47-73. PubMed ID: 19729801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioanalytical LC-MS of therapeutic oligonucleotides.
    van Dongen WD; Niessen WM
    Bioanalysis; 2011 Mar; 3(5):541-64. PubMed ID: 21388267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in validation, risk and uncertainty assessment of bioanalytical methods.
    Rozet E; Marini RD; Ziemons E; Boulanger B; Hubert P
    J Pharm Biomed Anal; 2011 Jun; 55(4):848-58. PubMed ID: 21237607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. European Bioanalysis Forum recommendation: scientific validation of quantification by accelerator mass spectrometry.
    Higton D; Young G; Timmerman P; Abbott R; Knutsson M; Svensson LD
    Bioanalysis; 2012 Nov; 4(22):2669-79. PubMed ID: 23210650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of bioanalytical LC-MS/MS assays: evaluation of matrix effects.
    Van Eeckhaut A; Lanckmans K; Sarre S; Smolders I; Michotte Y
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Aug; 877(23):2198-207. PubMed ID: 19179125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA perspective on specifications for biotechnology products--from IND to PLA.
    Murano G
    Dev Biol Stand; 1997; 91():3-13. PubMed ID: 9413677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absolute quantitation of protein therapeutics in biological matrices by enzymatic digestion and LC-MS.
    Li F; Fast D; Michael S
    Bioanalysis; 2011 Nov; 3(21):2459-80. PubMed ID: 22074286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biotherapeutic bioanalysis: a multi-indication case study review.
    Myler HA; Given A; Kolz K; Mora JR; Hristopoulos G
    Bioanalysis; 2011 Mar; 3(6):623-43. PubMed ID: 21417732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulated drug bioanalysis for human pharmacokinetic studies and therapeutic drug management.
    Huang Y; Shi R; Gee W; Bonderud R
    Bioanalysis; 2012 Aug; 4(15):1919-31. PubMed ID: 22943622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.